¼¼°èÀÇ ÅäÅ» ½ÇÇè½Ç ÀÚµ¿È­ ½ÃÀå
Total Lab Automation
»óǰÄÚµå : 1796038
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 395 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,245,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,736,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÅäÅ» ½ÇÇè½Ç ÀÚµ¿È­ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 85¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 60¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÅäÅ» ½ÇÇè½Ç ÀÚµ¿È­ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 5.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 85¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀÚµ¿ ¾×ü Çڵ鷯´Â CAGR 6.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 36¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÚµ¿ Ç÷¹ÀÌÆ® Çڵ鷯 ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 16¾ï ´Þ·¯, Áß±¹Àº CAGR 9.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÅäÅ» ½ÇÇè½Ç ÀÚµ¿È­ ½ÃÀåÀº 2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 18¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 9.5%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.9%¿Í 5.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÅäÅ» ½ÇÇè½Ç ÀÚµ¿È­ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÅäÅ» ½ÇÇè½Ç ÀÚµ¿È­´Â Á¶»ç ¹× Áø´Ü¿¡ ¾î¶² º¯È­¸¦ °¡Á®¿Ã °ÍÀΰ¡?

ÅäÅ» ½ÇÇè½Ç ÀÚµ¿È­(TLA)´Â ·Îº¿ °øÇÐ, ÀÚµ¿ ÄÁº£À̾î, ¾×ü Çڵ鷯, Áö´ÉÇü ½ºÄÉÁÙ¸µÀ» ÀÓ»ó, Á¦¾à, ¿¬±¸ ½ÇÇè½Ç¿¡ ÅëÇÕÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ½Ã·áÀÇ ¼±º°, ºÐ¼®, º¸°ü, º¸°ü, ¾ÆÄ«À̺ùÀ» ¿øÈ°ÇÏ°Ô °ü¸®ÇÏ°í ¼öÀÛ¾÷À¸·Î ÀÎÇÑ ÅÍÄ¡ Æ÷ÀÎÆ®¸¦ ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. TLA´Â º´¸ñÇö»óÀ» ÇØ¼ÒÇϰí 24½Ã°£ 365ÀÏ Ç¥ÁØÈ­µÈ ¿öÅ©Ç÷ο츦 º¸ÀåÇÕ´Ï´Ù. À̸¦ ÅëÇØ ½ÇÇè½ÇÀº ´ë·®ÀÇ »ùÇÃÀ» Á¤È®ÇÏ°Ô Ã³¸®Çϰí Áß¿äÇÑ Áø´Ü °á°ú¿¡ ´ëÇÑ ¼Ò¿ä ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. °Ë»çÁ¤º¸°ü¸® ½Ã½ºÅÛ(LIMS)°úÀÇ ÅëÇÕÀ» ÅëÇØ °Ë»ç ÇÁ·ÎÅäÄÝ ¹× ½Ã¾à »ç¿ë ÇöȲÀ» Áß¾Ó¿¡¼­ ¸ð´ÏÅ͸µ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

TLA¸¦ °­È­ÇÏ´Â ±â¼ú Çõ½ÅÀ̶õ?

ÃÖ÷´Ü TLA Ç÷§ÆûÀº ÇöÀç AI¸¦ Ȱ¿ëÇÑ ½ºÄÉÁÙ¸µ, ¿¹Áöº¸Àü, ½ÇÇè½ÇÀÇ ¼ºÀå¿¡ µû¸¥ ¸ðµâ½Ä È®ÀåÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ·Îº¿ ÆÈÀº ¹ÙÄڵ尡 ºÎÂøµÈ Æ©ºê ÃßÀû ¹× ºñÀü ½Ã½ºÅÛÀ» »ç¿ëÇÏ¿© ´Ù¾çÇÑ ÄÁÅ×ÀÌ³Ê Æ÷¸Ë¿¡ ´ëÀÀÇÕ´Ï´Ù. °í±Þ ¼¾¼­°¡ ¿Âµµ, ¿¡¾î·ÎÁ¹ ¾ÈÀü, ¿À¿° ¹æÁö¸¦ ¸ð´ÏÅ͸µÇÕ´Ï´Ù. ¾×ü Ãë±Þ ÇÇÆêÆÃ ·Îº¿°ú º´·Ä ó¸®, ³·Àº µ¥µå º¼·ý ¼³°è¸¦ ÅëÇÕÇÏ¿© °í°¨µµ ºÐ¼® ¹× ºÐÀÚÁø´ÜÀ» Áö¿øÇÕ´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ÅëÇÕÀº ºí·ÏüÀο¡ ´ëÀÀÇÏ´Â °¨»ç ÃßÀûÀ¸·Î ±ÔÁ¦ Áؼö¸¦ °­È­Çϰí, ¿ø°Ý ¸ð´ÏÅ͸µÀ» È®´ëÇÕ´Ï´Ù.

¿ÏÀü ÀÚµ¿È­ µµÀÔÀ» ¼±µµÇÏ´Â ¿¬±¸¼Ò´Â?

ÇÏÀ̽º·çDz Áø´Ü¼¾ÅÍ¿¡¼­´Â TLA¸¦ ÅëÇØ ¸ÅÀÏ ¼ö½Ê¸¸ °ÇÀÇ COVID-19 ¹× À¯ÀüÀÚ °Ë»ç »ùÇÃÀ» ó¸®Çϰí ÀÖ½À´Ï´Ù. Á¦¾à R&D¿¡¼­´Â ÀϰüµÈ ¿öÅ©Ç÷οì·Î Èĺ¸ ¶óÀ̺귯¸®¸¦ ½ºÅ©¸®´×Çϱâ À§ÇØ TLA¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¹ðÅ©´Â Á¤È®ÇÑ ½Ã·áÀÇ È¸¼ö ¹× ¹®¼­È­¸¦ À§ÇØ ÀÚµ¿ Àú¿ÂÀúÀå ½Ã½ºÅÛÀ» »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ´ëÇÐÀÇ ÇÙ½É ½Ã¼³¿¡¼­´Â À¯¿¬¼ºÀÌ ÇÊ¿äÇÑ ´Ü¹éÁúüÇÐ ¹× ¼¼Æ÷ ±â¹Ý ºÐ¼®¿¡ ¸ðµâÇü ½Ã½ºÅÛÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. º´¿øÀÇ ÂüÁ¶ ½ÇÇè½ÇÀº ±Ô¸ð¿Í ǰÁú ±âÁØÀÇ ¿ä±¸·Î ÀÎÇØ ÀÏ»óÀûÀÎ Ç÷¾×ÇÐ, È­ÇÐ, ¹Ì»ý¹°ÇÐ °Ë»ç¿¡ TLA¸¦ äÅÃÇϰí ÀÖ½À´Ï´Ù.

TLA ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀº?

ÅäÅ» ½ÇÇè½Ç ÀÚµ¿È­ÀÇ ¼ºÀå ¿øµ¿·ÂÀº ½Å¼ÓÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ³ëµ¿·Â ºÎÁ·, ÀÇ·á ¹× Á¦¾à ºÐ¾ßÀÇ ¾ö°ÝÇÑ Ç°Áú º¸ÁõÀÔ´Ï´Ù. GMP, GLP, ÃßÀû¼º, ÀÎÀû ¿À·ù °¨¼Ò¿Í °°Àº ±ÔÁ¦Àû ¾Ð¹ÚÀÌ ½ÇÇè½ÇÀÇ ÀÚµ¿È­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í À¯ÀüüÇÐ ¿öÅ©Ç÷οìÀÇ È®»êÀ¸·Î »ùÇà 󸮷®ÀÌ ºñ¾àÀûÀ¸·Î Áõ°¡Çß½À´Ï´Ù. ±Ô¸ðÀÇ °æÁ¦¸¦ ÅëÇÑ È¿À²¼º Çâ»ó°ú °Ë»ç´ç ºñ¿ë Àý°¨Àº Ãʱâ ÅõÀÚ¸¦ Á¤´çÈ­ÇÕ´Ï´Ù. ¶ÇÇÑ, µ¥ÀÌÅÍ ±â¹Ý ½ÇÇè½Ç°ú AI Áö¿ø ¿öÅ©Ç÷οì·ÎÀÇ ÀüȯÀº º¥´õµéÀÇ ±â¼ú Çõ½Å°ú ´ë±Ô¸ð ÀÚº» ÅõÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

±â±â À¯Çü(ÀÚµ¿ ¸®Äûµå Çڵ鷯, ÀÚµ¿ Ç÷¹ÀÌÆ® Çڵ鷯, ·Îº¿ ¾Ï, ÀÚµ¿ â°í(ASRS), ºÐ¼®±â), ¼ÒÇÁÆ®¿þ¾î(½ÇÇè½Ç Á¤º¸ °ü¸® ½Ã½ºÅÛ ¼ÒÇÁÆ®¿þ¾î, ½ÇÇè½Ç Á¤º¸ ½Ã½ºÅÛ ¼ÒÇÁÆ®¿þ¾î, Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ ¼ÒÇÁÆ®¿þ¾î, ÀüÀÚ¿¬±¸³ëÆ® ¼ÒÇÁÆ®¿þ¾î, °úÇÐ µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ ¼ÒÇÁÆ®¿þ¾î), ¿ëµµ(Drug Discovery ¿ëµµ, À¯ÀüüÇÐ ¿ëµµ, ´Ü¹éÁúüÇÐ ¿ëµµ, ÀÓ»ó Áø´Ü ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Total Lab Automation Market to Reach US$8.5 Billion by 2030

The global market for Total Lab Automation estimated at US$6.0 Billion in the year 2024, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Automated Liquid Handlers, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Automated Plate Handlers segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 9.5% CAGR

The Total Lab Automation market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Total Lab Automation Market - Key Trends & Drivers Summarized

How Is Total Lab Automation Transforming Research and Diagnostics?

Total Lab Automation (TLA) integrates robotics, automated conveyors, liquid handlers, and intelligent scheduling into clinical, pharmaceutical, or research labs. These systems seamlessly manage sample sorting, analysis, storage, and archiving, minimizing manual touchpoints. TLA eliminates bottlenecks and ensures 24/7 standardized workflow, enabling labs to process high sample volumes with precision and reducing turnaround times for critical diagnostic results. Integration with Laboratory Information Management Systems (LIMS) provides centralized oversight over test protocols and reagent usage.

What Technological Innovations Are Empowering TLA?

State-of-the-art TLA platforms now offer AI-powered scheduling, predictive maintenance, and modular expansion in line with lab growth. Robotics arms use barcoded tube tracking and vision systems to handle diverse container formats. Advanced sensors monitor temperature, aerosol safety, and contamination avoidance. Integration of liquid-handling pipetting robots with parallel processing and low-dead-volume design supports high-sensitivity assays and molecular diagnostics. Cloud-based integration extends remote monitoring, with blockchain-enabled audit trails enhancing regulatory compliance.

Which Labs Are Leading Adoption of Full Automation?

High-throughput diagnostics centers rely on TLA to process hundreds of thousands of daily COVID-19 or genetic test samples. Pharma R&D deploys TLA for screening candidate libraries with consistent workflow. Biobanks use automated cryo-storage systems for precise sample retrieval and documentation. University core facilities deploy modular systems for proteomics and cell-based assays requiring flexibility. Hospital reference labs favor TLA for routine hematology, chemistry, and microbiology testing driven by scale and quality-standards demand.

What Is Fueling the Expansion of TLA Market?

The growth in total lab automation is driven by rising demand for rapid diagnostics, labor shortages, and strict quality assurance in healthcare and pharma. Regulatory pressure for GMP, GLP, traceability, and reduced human error encourages labs to automate. Rising prevalence of personalized medicine and genomics workflows exponentially increase sample throughput. Efficiency gains from economies of scale and reduced per-test cost justify initial investments. In addition, the shift to data-driven labs and AI-enabled workflows continues to fuel vendor innovation and heavy capital adoption.

SCOPE OF STUDY:

The report analyzes the Total Lab Automation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Equipment Type (Automated Liquid Handlers, Automated Plate Handlers, Robotic Arms, Automated Storage & Retrieval Systems, Analyzers); Software (Laboratory Information Management System Software, Laboratory Information System Software, Chromatography Data System Software, Electronic Lab Notebook Software, Scientific Data Management System Software); Application (Drug Discovery Application, Genomics Application, Proteomics Application, Clinical Diagnostics Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â